STERIS Expects FY25 As Reported Revenue From Continuing Operations To Increase 6.5%-7.5%; Adjusted EPS From Continuing Operations Of $9.05 - $9.25 (Est $9.33)
Portfolio Pulse from Benzinga Newsdesk
STERIS projects FY25 revenue from continuing operations to grow by 6.5%-7.5% and forecasts adjusted EPS from continuing operations to be between $9.05 and $9.25, slightly below the estimated $9.33. Capital expenditures are expected to be around $360 million, with free cash flow projected at $700 million.
May 08, 2024 | 9:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
STERIS expects FY25 revenue growth of 6.5%-7.5% and adjusted EPS from continuing operations of $9.05-$9.25, below analysts' expectations of $9.33. Capital expenditures are projected at $360 million, with free cash flow around $700 million.
The projected revenue growth and adjusted EPS indicate a positive outlook for STERIS, although the EPS forecast is slightly below market expectations. The significant capital expenditures suggest ongoing investments in growth or operational efficiency, while the strong free cash flow projection is a positive indicator of financial health. However, the slight miss on the EPS estimate could temper investor enthusiasm in the short term, leading to a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100